United States - English - NLM (National Library of Medicine)

abbvie inc. - beractant (unii: s866o45pig) (beractant phospholipids - unii:lja7v5fcw8) - calfactant 25 mg in 1 ml - survanta is indicated for prevention and treatment (“rescue”) of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. none

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - beractant, quantity: 25 mg/ml - suspension - excipient ingredients: colfosceril palmitate; tripalmitin; palmitic acid; sodium chloride; phosphatidyl choline; water for injections - prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - beractant - suspension for endotracheopulmonary instillation - 25mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - beractant -

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

abbvie inc. - beractante: surfactante pulmonar bovino, fosfolÍpidos - beractante: surfactante pulmonar bovino, fosfolÍpidos....25.00 mg

Canada - English - Health Canada

abbvie corporation - beractant - suspension - 25mg - beractant 25mg - pulmonary surfactants

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - beractant (phospolipids)-lung -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - beractant (phospolipids)-lung -

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - phospholipids - solution, sterile - 25 mg/ml - phospholipids 25 mg/ml

Philippines - English - FDA (Food And Drug Administration)

zuellig pharma corporation; distributor: zuellig pharma corporation - survanta - suspension for intratracheal administration - 25 mg/ml